• Research & Development

  PhaseBio Starts Phase 2b Trial to Test PB1046 in PAH Patients

  Posted by Pulmonary Hypertension News Moderator on December 4, 2018 at 1:15 pm

  PhaseBio has started dosing its investigational compound PB1046 in patients with PAH to assess its safety, tolerability, and therapeutic activity. Click here to read more.

  Are you interested in this research?

  replied 7 years, 3 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply